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Abstract
Background
Long-term inhaled corticosteroids (ICS) may reduce growth velocity and final height of chil-
dren with asthma. We aimed to evaluate the association between ICS use of >12 months
and growth.
Methods
We initially searched MEDLINE and EMBASE in July 2013, followed by a PubMed search
updated to December 2014. We selected RCTs and controlled observational studies of ICS
use in patients with asthma. We conducted random effects meta-analysis of mean differ-
ences in growth velocity (cm/year) or final height (cm) between groups. Heterogeneity was
assessed using the I2 statistic.
Results
We found 23 relevant studies (twenty RCTs and three observational studies) after screen-
ing 1882 hits. Meta-analysis of 16 RCTs showed that ICS use significantly reduced growth
velocity at one year follow-up (mean difference -0.48 cm/year (95% CI -0.66 to -0.29)).
There was evidence of a dose-response effect in three RCTs. Final adult height showed a
mean reduction of -1.20 cm (95% CI -1.90 cm to -0.50 cm) with budesonide versus placebo
in a high quality RCT. Meta-analysis of two lower quality observational studies revealed
uncertainty in the association between ICS use and final adult height, pooled mean differ-
ence -0.85 cm (95% CI -3.35 to 1.65).
Conclusion
Use of ICS for >12 months in children with asthma has a limited impact on annual growth
velocity. In ICS users, there is a slight reduction of about a centimeter in final adult height,
which when interpreted in the context of average adult height in England (175 cm for men
and 161 cm for women), represents a 0.7% reduction compared to non-ICS users.
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Introduction
Inhaled corticosteroids (ICS) are amongst the most important treatment options in persistent
asthma because of their efficacy in suppressing the inflammatory response. The clinical benefits
of long-term therapy with ICS are consistently emphasized in national and international guide-
lines (United Kingdom and United States). [1, 2] However, there have been widespread, long-
standing concerns regarding adverse events (such as fractures, and reduction of growth in chil-
dren) with corticosteroids. [3, 4] The James Lind Alliance (in partnership with the British Tho-
racic Society and Asthma UK) reported on a recent prioritization exercise involving patients
and health care professionals where adverse effects of corticosteroids was judged to be a top
research priority. [5]
One of the major areas of concern and uncertainty is the potential for reduction in growth
velocity and final height of children who are long-term users of inhaled corticosteroids (ICS).
In 2006, Pedersen conducted a systematic review on randomized controlled trials (RCTs)
of> 12 months ICS use in children, and concluded that there was possibly a small decrease in
statural growth. [6] In an expert symposium, Skoner et al. noted a similar small decrease in
growth, and an increase in cataracts, but argued that the earlier studies were methodologically
weak, or based on drugs no longer in common use. [7]
Recent recommendations on comprehensive evaluations of adverse effects have suggested
that a wide range of study designs (beyond just RCTs) may need to considered, depending on
the features of the adverse outcome of interest. [8] Rare adverse events, or those that occur
only after prolonged therapy, can be evaluated with non-randomized studies, perhaps even
requiring a meta-analysis of various study designs. [8] Hence we aimed to analyse the effects of
long-term (>12 months) ICS use in children with asthma, concentrating on growth velocity
and final adult height in randomized and non-randomized studies.
Methods
Study Selection Criteria
As we were interested in long-term adverse effects that may be of relatively small magnitude,
we selected studies with> 20 users of each ICS formulation, and follow-up of at least 52 weeks
duration.
Our inclusion criteria for RCTs were (1) parallel-group RCT; (2) children with asthma of
any severity; (3) ICS as the intervention vs a control treatment, where the comparison groups
consisted of ICS vs other treatment, or ICS in combination with LABA vs a LABA alone; and
(4) stated aim to evaluate growth velocity and/or final adult height.
We also evaluated controlled observational studies (case control, prospective cohort or ret-
rospective cohort) reporting on growth velocity and/or height with any ICS exposure com-
pared to those without ICS exposure.
We excluded studies that recruited children where the diagnosis of asthma had not been
established. We excluded crossover trials and studies that considered only oral corticosteroid
use without reporting the effects of inhaled corticosteroids.
Search Strategy
We initially searched MEDLINE and EMBASE in June 2013 using a broad strategy for a wide
range of adverse effects, and we updated this with a more focused PubMed search in December
2014 (see S1 Appendix for search terms and restrictions). We also checked the bibliographies
of included studies and existing systematic reviews for relevant articles.
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Study Selection
Two reviewers (MT and PB) independently, and in duplicate considered all titles and abstracts.
At this point, we excluded reports that were clearly not RCTs or observational studies of ICS in
asthma. We then retrieved full text versions of potentially relevant articles and carried out fur-
ther screening to determine if the study objectives included the evaluation of growth. A third
researcher (YKL) finalized the decision during discussion with the two reviewers.
Study Characteristics and Data Extraction
We extracted data onto pre-formatted tables with details on study design, participants, defini-
tion of asthma, drug therapy (dose, device and frequency), and duration of follow-up. Two
reviewers independently extracted data (MT and PB) on final adult height and growth velocity
(cm per year). A third reviewer (YKL) corrected any discrepancies after rechecking the source
papers.
Risk of Bias Assessment
Two reviewers (MT and PB) independently assessed the reporting of blinding, allocation con-
cealment, withdrawals and the loss to follow-up in RCTs. In accordance with recommenda-
tions on assessing adverse effects, we extracted information on participant selection,
ascertainment of exposure and outcomes, and methods of addressing confounding in observa-
tional studies. [9] A third reviewer (YKL) adjudicated and made the final decision on discrep-
ant items after rechecking the source papers.
We aimed to use a funnel plot to assess publication bias if there were>10 studies in the
meta-analysis, with no significant heterogeneity seen. [10]
Statistical Analysis
We pooled trial data using Review Manager (RevMan) version 5.3.2 (Nordic Cochrane Center,
Copenhagen, Denmark). We used the inverse variance method to pool mean differences in
growth velocity (cm per year) or final adult height (cm) between ICS users and non-users. We
calculated the I2 statistic to for statistical heterogeneity with I2> 50% indicating a substantial
level of heterogeneity. [11]
If a study had multiple arms involving different ICS doses, we attempted to analyse data on
the licensed dose for children where available, otherwise we combined all the intervention
arms together as recommended by the Cochrane Handbook. [12] For studies with more than
one group of non-ICS users, we analysed data from the placebo arm (wherever possible) in
preference to data from active comparators such as nedocromil or montelukast. If the study
reported growth velocity values at different points over a number of years, we analysed the data
based on the first year, but also recorded the overall change over the complete follow-up, as
well as at different annual intervals. For studies that did not explicitly report growth velocity,
we extracted data on the mean change in height from baseline to the 52 week follow-up. In
accordance with the recommendations of the Cochrane Handbook, we imputed any standard
deviations from 95% confidence intervals or p-values. [13]
Subgroup Analysis
We aimed to conduct subgroup analysis where growth data were available for head to head
comparisons of different treatment regimens (dose / duration), or for children of different ages
within the same study.
We do not have a pre-registered protocol.
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Results
We screened 1882 potentially relevant articles, and finally included 23 studies in our systematic
review (comprising twenty RCTs, [14–33] and three observational studies [34–36]). The pro-
cess of study selection is shown in S1 Fig.
S1 and S2 Tables show the characteristics of the included RCTs, and the observational stud-
ies respectively. S3 and S4 Tables report on study validity and outcomes.
The study with the longest treatment duration was four years (CAMP—Childhood Asthma
Management Programme), [24] while the remaining trials had ICS therapy for between 52–
156 weeks. The ICS formulations reported in the trials included beclometasone, budesonide,
ciclesonide, flunisolide, fluticasone, and mometasone. There was variation in the choice of con-
trol intervention, with placebo, nedocromil, montelukast, sodium cromoglicate being used in
some trials. We identified three trials where budesonide and fluticasone were compared head-
to-head, without any non-ICS control arm. [14, 18, 19]
The observational studies looked at narrow range of ICS users, primarily focusing on bude-
sonide (two studies), [34, 35] whilst one study did not specify ICS formulation.[36]
Study Validity
Randomized Controlled Trials (n = 20). Nine of the RCTs reported an appropriate
method of sequence generation, eleven provided details on how concealment of allocation was
achieved whilst 13 reported the use of double blinding. (S2 Table). Ascertainment of height
was usually done through stadiometry. S2 Table also shows that discontinuations and substan-
tial losses to follow-up (particularly where height was not available at final timepoint) are
major limitation affecting almost all the trials. The vast majority of trials had involvement of
pharmaceutical industry sponsors.
Observational studies (n = 3). Overall, we considered the studies to be at moderate to
high risk of bias due to potentially confounded comparisons arising from the relatively limited
matching and lack of multivariate adjustment.
Outcomes: Growth Velocity
Sixteen RCTs and one observational study reported on comparative difference in growth veloc-
ity (cm/year) in children. (Fig 1) Overall, ICS use was associated with significant reductions in
growth velocity as compared to controls in RCTs (pooled Mean difference -0.48 cm/year1; 95%
CI -0.66–0.29 cm/year; I2 = 48%). We demonstrated that agents such as beclometasone, bude-
sonide, and fluticasone were all individually associated with significant reductions in growth
velocity compared to non-users. However, there was only sparse data available for other for-
mulations such as ciclesonide (one trial), [29] flunisolide (two trials), [17, 21] or mometasone
(one trial), [30] and the broad confidence intervals reflect considerable uncertainty about treat-
ment effects.
The magnitude of reduction in growth velocity in the meta-analysis of RCTs was similar to
that seen with an observational study with 2.5 years’ follow-up in the Netherlands (Mean dif-
ference -0.44 cm/year; 95% CI -1.25 to 0.37 cm/year). [35] However, this study lacked power to
detect a difference as there were only 66 children available for analysis.
Outcomes: Final Adult Height
We identified one large long-term RCT of budesonide that captured final adult height in>90%
of the originally enrolled children. [24] This trial found that four years of budesonide use was
Inhaled Corticosteroids and Growth
PLOS ONE | DOI:10.1371/journal.pone.0133428 July 20, 2015 4 / 11
Fig 1. Growth Velocity in RCTS at 12 months follow-up.
doi:10.1371/journal.pone.0133428.g001
Fig 2. Final Adult Height, ICS users vs. non-users.
doi:10.1371/journal.pone.0133428.g002
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associated with a mean difference in final height of -1.2 cm (95% CI -1.9 − -0.5 cm) as com-
pared to those on placebo.
We identified two observational studies that reported reduction of between 0.7–0.9 cm in
final adult height. [34, 36] However, the sample sizes were small (leading to imprecise estimates
with broad confidence intervals) and a meta-analysis of the two observational studies showed a
mean difference of -0.85cm (95% CI -3.35–1.65, I2 = 0%). (Fig 2)
Subgroup Analysis Dose Response
We identified 3 RCTS where we were able to conduct head to head comparisons of growth
velocity between a higher dose and a lower dose of the same compound. [15, 29, 30] The trials
were not powered to identify statistically significant differences in growth velocity with ascend-
ing ICS doses or different ICS formulations. However, we noted a consistent finding towards
reduced growth velocities in the higher-dose arms relative to the lower-dose arms of the ICS,
with a pooled estimate confirming greater harm (p = 0.04)with higher doses overall. (Fig 3).
Subgroup Analysis Effect of Different ICS Compounds
Visual inspection of the Forest plot (Fig 1) suggests that magnitude of growth reduction may
differ amongst the ICS compounds. When we conducted subgroup testing for differences
between fluticasone and other ICS, we found that budesonide was not significantly worse
(p = 0.15), whereas beclometasone had a significantly greater adverse impact (p = 0.007).
This was corroborated in a direct head-to-head comparison where there was a significant
reduction in growth velocity of 0.91cm/year (95% CI 0.63–1.20) with beclometasone 400 mcg
daily compared to fluticasone 400 mcg daily. [18] In contrast, we identified divergent findings
in direct randomized trials comparing budesonide against fluticasone. Acun’s trial of budeso-
nide 400 mcg vs. fluticasone 250 mcg showed better growth velocity with budesonide (+0.37
cm/year), [14] whereas Ferguson’s study of budesonide 400 mcg vs fluticasone 200 mcg
reported significant adverse impact on growth velocity with budesonide of -0.9 cm/year (SE
0.19) compared to fluticasone. [19]
Fig 3. Mean Differences in Growth Velocity with Direct Comparison of Higher Dose vs. Lower Dose.
doi:10.1371/journal.pone.0133428.g003
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Subgroup Analysis Change in Growth Velocity by Duration of Follow-Up
We identified findings in three RCTs where ICS appeared to have the greatest adverse impact
on growth velocity in the first 12 months of the trial, whereas the reduction in growth velocity
was less problematic at 24 or 36 months follow-up. [25, 27, 37] For instance, the large CAMP
trial found a 1.7 cm/year reduction in growth velocity in the first 12 months for ICS versus con-
trol, but the difference in growth velocity was only about 0.1 cm at the 36 month follow-up.
[37]
In contrast, a smaller trial did not demonstrate any variation in effect of ICS on growth
velocity between the 12 and 24 months follow-up. [23]
Subgroup Analysis Age of Participants
Three trials reported the impact of ICS on growth for children of different age groups. [23–25]
Both Jonasson et al. and Pauwels et al. found that reduction in growth velocity with ICS was
more marked in those age11 years as compared to older children. [23, 25] The large CAMP
trial found that when compared to controls, ICS reduced final adult height by -1.9 cm (95% CI
-3.2 to -0.6 cm) in children entering the trial at age 5–8 years, whereas the reduction in final
adult height was -0.5 cm (95% CI -1.7 to -0.6 cm) in those entering at age 9–13 years. [24]
Reporting Biases
As there was substantial heterogeneity in the main analysis (Fig 1), we did not proceed to con-
struct a funnel plot. The potential direction of reporting biases in the included studies remains
unclear because we cannot judge conclusively if authors were more inclined to report signifi-
cant adverse effects, or conversely, to play down any indication of harm. However, as mostof
the studies involved commercial sponsors, we should be aware of the possibility of benefits
being emphasized, whilst harms are presented in less detail.
Discussion
Our meta-analysis of 23 studies confirms that long-term use>12 months of ICS is associated
with a slight reduction in growth velocity and final adult height in children. The reliability of
these results is supported by the concordance between the findings of the randomized and
non-randomized studies in direction and magnitude of effect. Moreover, we also identified
dose-responsiveness from direct randomized comparisons where lower doses of ICS were less
harmful than higher doses. Subgroup data indicates that adverse effects on growth may be
more prominent in younger children as opposed to older children. Equally, in trials where chil-
dren were followed-up for 24–36 months, we found that the reduction in growth velocity
appeared to be most prominent in the first year of therapy, and the magnitude of the adverse
effect seemed less problematic with time. This would tie in with the relatively limited diminu-
tion in final adult height, whereas we would have expected a cumulative decrement of several
centimeters if children had continued to fall behind by 0.5 cm for every cumulative year of ICS
therapy.
The effect size should be interpreted in the context of the average adult height of the popula-
tion. For instance, in England, the average adult height is 175.3 cm for men, and 161.6 cm for
women. [38] In an adult male, the reduction of around 1.2 cm would represent only a 0.68%
absolute diminution (from 175.3 cm to 174.1 cm). This might be considered as an almost
imperceptible or clinically insignificant change, particularly when weighted up against of the
proven benefits of ICS therapy. We should be conscious too that the reported 1.2 cm diminu-
tion probably represents a worst case scenario where participants in the RCT were using
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Budesonide 400 mcg daily continuously for a three year period, whereas real-world have their
doses titrated up and down according to disease severity. [39] In addition, adherence to ther-
apy, and therefore adverse effects of medication, is likely to be greater in a RCT than a real-
world setting.
There are a number of potential explanations for these findings. With longer durations of
follow-up, the initial adverse consequences on growth velocity may become less problematic if
the child has better-controlled asthma (thus enabling greater physical activity) and fewer exac-
erbations (associated with reduced need for acute short-courses of oral corticosteroids). More-
over, Pedersen has pointed out that children have different growth phases according to age. [6]
Hence, susceptibility to the adverse effects of ICS seems to be less of a problem in those above
the age of 10 years or more, which is a consistent finding in a number of trials.
Our findings are similar to those of recent Cochrane systematic reviews that have focused
principally on data from RCTs. [40, 41] In a meta-analysis of 15 RCTs, Zhang et al. reported
that ICS use was associated with significantly reduced growth velocity, mean difference of -0.48
cm/year as compared to controls. [41] In contrast to our review, Zhang et al. had selection cri-
teria that included RCTs of<12 months, but excluded observational studies. Pruteanu et al.
conducted a meta-analysis which demonstrated that higher ICS doses were associated with
greater reductions in growth velocity (a finding that is similar to ours), but they were unable to
identify significant differences amongst the ICS compounds. [40]
There are a number of limitations to our systematic review. Owing to the wide variety of
possible combinations of drug compounds, inhaler devices, and daily doses, we felt that it
would be scientifically inappropriate to draw conclusions through confounded indirect com-
parisons on dose or drug compound. Instead, we have limited our subgroup analyses to trials
that performed direct comparisons of dose or different ICS, and we do not have consistent evi-
dence that any specific compound is safer. The studies in our review date back 10–20 years and
the findings may be less applicable to current-day children in the face of better nutrition and
innovations in asthma management.
There are also a number of important limitations relating to validity of the primary studies.
Owing to the inherent difficulties in measuring long-term adverse events, there is potential for
considerable risk of bias (particularly from attrition) within this dataset. Moreover, the vast
majority of the trials were sponsored by the pharmaceutical industry, and the study methodol-
ogy (e.g. when choosing interventional dose and device) may have been designed towards
obtaining favourable results for the sponsored product. Equally, we should be wary of potential
reporting biases where positive findings are emphasized whereas negative ones are down-
played. This diversity amongst trial sponsors may have contributed towards the divergent find-
ings and increased heterogeneity in results.
Lack of information and inaccurate interpretation of the benefits and harms of ICS may hin-
der medication adherence in patients with asthma. [42] Although the evidence may be imper-
fect, our systematic review helps to address some of the concerns and uncertainty surrounding
the exact magnitude of growth reduction with ICS use. There is some indication of potential
differences between ICS formulations, with beclometasone possibly having a greater adverse
impact on growth. Prescribers and patients should aim for the lowest effective dose, particu-
larly if initiating ICS therapy for patients in the younger age groups who may be more suscepti-
ble to adverse effects.
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